Bloomberg
EsoBiotec’s platform has the potential to transform cell therapy, according to AstraZeneca, by empowering the immune system to attack cancers
Read More
AstraZeneca to buy EsoBiotec for up to $1 billion
EsoBiotec’s platform has the potential to transform cell therapy, according to AstraZeneca, by empowering the immune system to attack cancers